AEs leading to trial product discontinuation occurred in 51/603 (8.5%) participants in the CagriSema 2.4 mg/2.4 mg group, 40/605 (6.6%) participants in the semaglutide 2.4 mg group, 7/152 (4.6%) participants in the cagrilintide 2.4 mg group, 42/594 (7.1%) participants in the CagriSema 1 mg/1 mg group, 26/608 (4.3%) participants in the semaglutide 1 mg group, and 2/149 (1.3%) participants in the placebo group
Populations, endpoints, and individual outcomes vary
This is especially important for patients with absorption issues such as those with digestive conditions, low stomach acid (common with aging), or MTHFR gene variants who cannot adequately absorb B12 from food or oral supplements
Gluten-free breading for chicken, fish and vegetables
Lets understand how it works and whether its right for you
I think I will use it for the rest of my life